ATR and small cell lung carcinoma: A randomized phase 2 clinical trial of patients with small-cell lung cancer treated with ATR inhibitor berzosertib plus topotecan did not improve progression-free survival compared with topotecan therapy alone among patients with relapsed SCLC.